Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

RAET1E activates T cell-mediated cytotoxicity tumor cells.18Decreased Raet1e. 1 / 1

| 1

➶

eidos

"It has been shown to function as a ligand for both TCRgamma9delta2and NKG2D through which Raet1e induces T cell-mediated cytotoxicity to tumor cells.18Decreased Raet1e expression is a poor prognostic marker in nasopharyngeal carcinoma ,19 whereas high expression of Raet1e is an indicator of good prognosis in cervical cancer.20We first confirmed the MS finding of Raet1e 's overexpression by Western blot in WT and inUbr5 - / - cells treated with the proteasome inhibitor MG132 ( Figure 5a ) , which also indicated that Raet1e protein level was indeed regulated by a proteasome-mediated mechanism ."

32363114

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...